KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Asset Writedowns and Impairment: 2009-2025

Historic Asset Writedowns and Impairment for Neogenomics (NEO) over the last 10 years, with Sep 2025 value amounting to $7.1 million.

  • Neogenomics' Asset Writedowns and Impairment was N/A to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year change of. This contributed to the annual value of $450,000 for FY2024, which is 73.58% down from last year.
  • As of Q3 2025, Neogenomics' Asset Writedowns and Impairment stood at $7.1 million, which was down 64.64% from $20.0 million recorded in Q2 2025.
  • Neogenomics' 5-year Asset Writedowns and Impairment high stood at $20.0 million for Q2 2025, and its period low was $43,000 during Q3 2023.
  • Over the past 3 years, Neogenomics' median Asset Writedowns and Impairment value was $737,000 (recorded in 2023), while the average stood at $4.2 million.
  • Data for Neogenomics' Asset Writedowns and Impairment shows a maximum YoY plummeted of 84.29% (in 2024) over the last 5 years.
  • Neogenomics' Asset Writedowns and Impairment (Quarterly) stood at $718,000 in 2022, then reached $43,000 in 2023, then plummeted by 84.29% to $117,000 in 2024, then reached $7.1 million in 2025.
  • Its Asset Writedowns and Impairment was $7.1 million in Q3 2025, compared to $20.0 million in Q2 2025 and $117,000 in Q4 2024.